Abstract
Urokinase receptors (uPAR) were initially thought to function simply as a mechanism to concentrate the urokinase / plasmin system toward the cell surface. However, extensive evidence has accumulated that this glycolipidanchored receptor also functions in both the adhesive and signaling pathways of many migratory cells. Mechanisms by which uPAR exercises these functions involve complexing with other membrane proteins for signal transduction. One set of functional partners for uPAR on the cell surface are integrins. Recent studies point to important structural features of uPAR:integrin interactions, indicating uPAR to be a cis-acting integrin ligand. In vivo data reveal altered integrin function and cell migration when uPAR:integrin interactions are impaired. Together these observations support the idea that uPAR:integrin interactions may be a focal point of intervention in pathobiology where integrin function is crucial, such as tumor metastasis.
Current Pharmaceutical Design
Title: Urokinase Receptor and Integrin Interactions
Volume: 9 Issue: 19
Author(s): Matthias C. Kugler, Ying Wei and Harold A. Chapman
Affiliation:
Keywords: urokinase, integrin, adhesion, receptor
Abstract: Urokinase receptors (uPAR) were initially thought to function simply as a mechanism to concentrate the urokinase / plasmin system toward the cell surface. However, extensive evidence has accumulated that this glycolipidanchored receptor also functions in both the adhesive and signaling pathways of many migratory cells. Mechanisms by which uPAR exercises these functions involve complexing with other membrane proteins for signal transduction. One set of functional partners for uPAR on the cell surface are integrins. Recent studies point to important structural features of uPAR:integrin interactions, indicating uPAR to be a cis-acting integrin ligand. In vivo data reveal altered integrin function and cell migration when uPAR:integrin interactions are impaired. Together these observations support the idea that uPAR:integrin interactions may be a focal point of intervention in pathobiology where integrin function is crucial, such as tumor metastasis.
Export Options
About this article
Cite this article as:
Kugler C. Matthias, Wei Ying and Chapman A. Harold, Urokinase Receptor and Integrin Interactions, Current Pharmaceutical Design 2003; 9 (19) . https://dx.doi.org/10.2174/1381612033454658
DOI https://dx.doi.org/10.2174/1381612033454658 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Rho Kinase and Angiogenesis
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Physicochemical Properties that Determine Cellular Transport of Nanocarriers In Vitro and In Vivo
Current Organic Chemistry Tumor-Receptor Imaging in Breast Cancer: A Tool for Patient Selection and Response Monitoring
Current Molecular Medicine Vascular Biomarkers in Asthma and COPD
Current Topics in Medicinal Chemistry Pleiotropic Effects of Cathepsin D
Endocrine, Metabolic & Immune Disorders - Drug Targets Functional Evaluation of Imatinib mesylate in Hepatocellular Carcinoma Cells
Recent Patents on Biomarkers Cyclization in Opioid Peptides
Current Drug Targets Cannabinoids, Immune System and Cytokine Network
Current Pharmaceutical Design The Hepatocyte Growth Factor Receptor: Structure, Function and Pharmacological Targeting in Cancer
Current Signal Transduction Therapy Nanoparticle Systems Modulating Myeloid-Derived Suppressor Cells for Cancer Immunotherapy
Current Topics in Medicinal Chemistry Telomere Recombination and the ALT Pathway: A Therapeutic Perspective for Cancer
Current Pharmaceutical Design Inhibitors of Cancer Stem Cells
Anti-Cancer Agents in Medicinal Chemistry Tumor Dormancy and the Angiogenic Switch: Possible Implications of Bone Marrow- Derived Cells
Current Pharmaceutical Design Patent Selections:
Current Biomarkers (Discontinued) Xiao-Chai-Hu-Tang (XCHT) Intervening Irinotecan’s Disposition: The Potential of XCHT in Alleviating Irinotecan-Induced Diarrhea
Current Cancer Drug Targets Current Clinical Applications of In Vivo Magnetic Resonance Spectroscopy and Spectroscopic Imaging
Current Medical Imaging An Innovative Fluorescent Semi-quantitative Methylation-specific PCR Method for the Determination of MGMT Promoter Methylation is Reflecting Intra-tumor Heterogeneity
Current Cancer Drug Targets Current Issues in the Utility of Blood Oxygen Level Dependent MRI for the Assessment of Modulations in Tumor Oxygenation
Current Medical Imaging Targeting DNA Repair Proteins: A Promising Avenue for Cancer Gene Therapy
Current Gene Therapy Pharmaceutical Targeting of the Brain
Current Pharmaceutical Design